IRTC IRhythm Technologies Inc.

iRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas Recent Rate Publication

iRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas Recent Rate Publication

SAN FRANCISCO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, commented on the recent publication by Novitas Solutions (“Novitas”) of rates applicable to the Current Procedural Terminology (CPT) codes 93241, 93243, 93245 and 93247.

Following the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2021 Medicare Physician Fee Schedule (MPFS) Final Rule published on December 1, 2020, iRhythm has been coordinating with other industry participants to seek appropriate carrier pricing for CPT codes 93241, 93243, 93245 and 93247. iRhythm submitted a meeting request with Novitas on January 3, 2021. iRhythm anticipates meeting with Novitas but the meeting has not yet been scheduled.

The Company believes that the published rates by Novitas on January 29, 2021, are crosswalked from CPT codes 93224 and 93226, which are existing CPT codes for external continuous electrocardiographic recording up to 48 hours.

The Company is seeking additional information from Novitas and will provide updates as soon as practicable.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding CPT coding decisions, the company’s expectations regarding government and third-party payor adoption of CPT coding decisions and the timing thereof and other statements relating to reimbursement coverage. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filing made with the Securities and Exchange Commission on the Form 10-Q on November 6, 2020. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact

Leigh Salvo

(415) 937-5404





Media Contact

Saige Smith  

(262) 289-7065



EN
29/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

 PRESS RELEASE

iRhythm Technologies to Report First Quarter 2024 Financial Results on...

iRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024 SAN FRANCISCO, April 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2024 after the close of trading on Thursday, May 2, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation...

 PRESS RELEASE

iRhythm Announces Closing of $661.25 Million of 1.50% Convertible Seni...

iRhythm Announces Closing of $661.25 Million of 1.50% Convertible Senior Notes Due 2029, Including Full Exercise of Initial Purchasers’ $86.25 Million Option to Purchase Additional Notes SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict and help prevent disease, announced today the closing of its offering of 1.50% Convertible Senior Notes due 2029 (the “notes”) for gross proceeds of $661.25 million in a private placement to persons reasona...

 PRESS RELEASE

iRhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible...

iRhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible Senior Notes Due 2029 SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict and help prevent disease, announced today the pricing of its offering of $575.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Secu...

 PRESS RELEASE

iRhythm Announces Proposed Offering of $450.0 Million of Convertible S...

iRhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and help prevent disease, announced today that it intends to offer, subject to market conditions and other factors, $450.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to...

 PRESS RELEASE

iRhythm collaborates with Epic to streamline access to Zio® service an...

iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and preve...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch